慢性乙型肝炎和原发性肝癌患者中腺病毒中和抗体的流行病学研究

被引：0

作者：

熊域皎

机构：

[1] 重庆医科大学

关键词：

慢性乙型肝炎; 原发性肝癌; 腺病毒; 中和抗体;

D O I：

暂无

年度学位：

2015

学位类型：

硕士

导师：

贾蓓;

摘要：

目的：调查慢性乙型病毒性肝炎(CHB)和原发性肝癌(HCC)患者体内人腺病毒5型(AdHu5),26型(AdHu26)和猿腺病毒68型(AdC68)的中和抗体流行率,为这两类疾病开发安全有效的生物治疗载体提供依据。方法：我们收集196份慢性乙型病毒性肝炎患者血清和193份原发性肝癌患者血清,通过腺病毒中和实验检测血清中AdHu5、AdHu26和AdC68的中和抗体。结果：在慢性乙型病毒性肝炎患者中AdHu5、AdHu26和AdC68的中和抗体阳性率分别为84.7%(95%可信区间：79.0-89.1%),58.2%(95%可信区间：51.2-64.9%),39.8%(95%可信区间：33.2-46.8%)；在原发性肝癌患者中AdHu5、AdHu26和AdC68的中和抗体阳性率分别为75.1%(95%可信区间：68.6-80.7%),66.8%(95%可信区间：59.9-73.1%),32.1%(95%可信区间：25.9-39.0%)。结论：本实验中,AdC68的中和抗体的流行率和抗体滴度都最低,其作为CHB和HCC的生物治疗载体较AdHu5与AdHu26具有优势。

引用

页数：50

共 36 条

[21]

IL-12 promotes HBV-specific central memory CD8 + T cell responses by PBMCs from chronic hepatitis B virus carriers.[J].Shi-Qiu Xiong;Bing-Liang Lin;Xiang Gao;Hao Tang;Chang-You Wu.International Immunopharmacology.2006, 5

[22]

Genital CD8 + T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus.[J].Ana Paula D. de Souza;Larissa H. Haut;Renata Silva;Silvia I.A.C.P. Ferreira;Carlos R. Zanetti;Hildegund C.J. Ertl;Aguinaldo R. Pinto.Vaccine.2006, 1

[23]

Cellular and virological mechanisms of HBV drug resistance.[J].Stephen Locarnini;William S. Mason.Journal of Hepatology.2005, 2

[24]

Prevention of hepatitis B virus–related hepatocellular carcinoma.[J].Anna S.F. Lok.Gastroenterology.2004, 5

[25]

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures [J].

Lavanchy, D .

JOURNAL OF VIRAL HEPATITIS, 2004, 11 (02) :97-107

[26]

Induction of CD8 + T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector.[J].A.R. Pinto;J.C. Fitzgerald;G.P. Gao;J.M. Wilson;H.C.J. Ertl.Vaccine.2003, 5

[27]

The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells [J].